Pomalidomide plus Low-Dose Dexamethasone plus Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

被引：0

作者：

Siegel, David S. ^{[1
,2
]}

Schiller, Gary J. ^{[3
]}

Samaras, Christy J. ^{[4
]}

Sebag, Michael ^{[5
]}

Berdeja, Jesus G. ^{[6
]}

Ganguly, Siddhartha ^{[7
]}

Matous, Jeffrey V. ^{[8
]}

Song, Kevin ^{[9
]}

Seet, Christopher S. ^{[10
]}

Talamo, Giampaolo ^{[11
]}

Acosta-Rivera, Mirelis ^{[12
]}

Bar, Michael ^{[13
]}

Quick, Donald P. ^{[14
]}

Anz, Bertrand ^{[15
]}

Fonseca, Gustavo ^{[16
]}

Reece, Donna ^{[17
]}

Agarwal, Amit ^{[18
]}

Chung, Weiyuan ^{[18
]}

Zafar, Faiza ^{[18
]}

Bahlis, Nizar ^{[19
]}

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Myeloma Div, Hackensack, NJ USA

[2] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Lymphoma Div, Hackensack, NJ USA

[3] UCLA, David Geffen Sch Med, Los Angeles, CA USA

[4] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[5] McGill Univ, Hlth Ctr, Montreal, PQ, Canada

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Univ Kansas, Ctr Canc, Fairway, KS USA

[8] Colorado Blood Canc Inst, Denver, CO USA

[9] Vancouver Gen Hosp, Vancouver, BC, Canada

[10] UCLA, Med Ctr, Los Angeles, CA USA

[11] Penn State Hershey Canc Inst, Hershey, PA USA

[12] Fdn Invest, San Juan, PR USA

[13] Stamford Hosp, Stamford, CT USA

[14] Joe Arrington Canc Res Treatment Ctr, Lubbock, TX USA

[15] Tennessee Oncol, Chattanooga, TN USA

[16] Florida Canc Specialists, St Petersburg, FL USA

[17] Princess Margaret Canc Ctr, Toronto, ON, Canada

[18] Celgene Corp, Summit, NJ USA

[19] Univ Calgary, Calgary, AB, Canada

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-111920

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3271

引用

页数：4

共 50 条

[41] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Chari, Ajai
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
Oriol, Albert
Arnulf, Bertrand
Rodriguez-Otero, Paula
Pineiro, Luis
Jakubowiak, Andrzej
de Boer, Carla
Wang, Jianping
Clemens, Pamela L.
Ukropec, Jon
Schecter, Jordan
Lonial, Sagar
Moreau, Philippe
BLOOD, 2019, 134 (05) : 421 - 431
[42] Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study
Terpos, Evangelos
Repousis, Panagiotis
Lalayanni, Chrysavgi
Hatjiharissi, Evdoxia
Assimakopoulou, Theodora
Vassilopoulos, Georgios
Pouli, Anastasia
Spanoudakis, Emmanouil
Michalis, Eurydiki
Pangalis, Gerassimos
Ntanasis-Stathopoulos, Ioannis
Poziopoulos, Christos
Kyrtsonis, Marie-Christine
Pappa, Vasiliki
Symeonidis, Argiris
Georgopoulos, Christos
Zikos, Panagiotis M.
Gavriatopoulou, Maria
Papadaki, Helen A.
Dadakaridou, Magdalini
Karvounis-Marolachakis, Kiki
Katodritou, Eirini
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (07)
[43] POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: PHASE 1 PHARMACOKINETICS AND SAFETY
Matous, J.
Siegel, D.
Lonial, S.
Harvey, R. D.
Kasserra, C.
Li, Y.
Chen, M.
Doerr, T.
Sternas, L.
Zaki, M.
Jacques, C.
Shah, J.
HAEMATOLOGICA, 2015, 100 : 507 - 508
[44] Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison
Van Sanden, Suzy
Ito, Tetsuro
Diels, Joris
Vogel, Martin
Belch, Andrew
Oriol, Albert
ONCOLOGIST, 2018, 23 (03): : 279 - 287
[45] Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Lonial, Sagar
Vij, Ravi
Harousseau, Jean-Luc
Facon, Thierry
Moreau, Philippe
Mazumder, Amitabha
Kaufman, Jonathan L.
Leleu, Xavier
Tsao, L. Claire
Westland, Christopher
Singhal, Anil K.
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1953 - 1959
[46] Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma
Wang, Chunling
He, Zhengmei
Shi, Yuye
Zhang, Lijuan
Chen, Yue
Chen, Zhi
Yu, Liang
HEMATOLOGY, 2017, 22 (02) : 88 - 92
[47] Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
Dosne, Anne-Gaelle
Li, Xia
Luo, Man Melody
Nnane, Ivo
Dimopoulos, Meletios A.
Terpos, Evangelos
Sonneveld, Pieter
Kampfenkel, Tobias
Carson, Robin
Amin, Himal
Ruixo, Juan Perez
Zhou, Honghui
Sun, Yu-Nien
Xu, Yan
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (05) : 1640 - 1655
[48] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
Nikhil C Munshi
Constantine Mitsiades
Paul G Richardson
Kenneth C Anderson
Nature Clinical Practice Oncology, 2008, 5 : 374 - 375
[49] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
Munshi, Nikhil C.
Mitsiades, Constantine
Richardson, Paul G.
Anderson, Kenneth C.
NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 374 - 375
[50] Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma
Fukushima, Toshihiro
Nakamura, Takuji
Iwao, Haruka
Umehara, Hisanori
AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (10) : 893 - 893

← 1 2 3 4 5 →